NEW YORK, July 19, 2017 /PRNewswire/ --
If you want a Stock Review on RNN, PLX, NAVB, or BSTG then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Pre-market,
DailyStockTracker.com scans Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Protalix BioTherapeutics Inc. (NYSE MKT: PLX), Navidea
Biopharmaceuticals Inc (NYSE MKT: NAVB), and Biostage Inc. (NASDAQ: BSTG). According to an article on InvestorPlace, Biotech and
Pharma stocks have bounced back this year. The SPDR S&P Biotech ETF has gained 34% in 2017, and the iShares NASDAQ
Biotechnology Index ETF has gained 19%. Learn more about these stocks by signing up for their free reports on
DailyStockTracker.com at: http://dailystocktracker.com/register/
Rexahn Pharma
On Tuesday, shares in Rockville, Maryland headquartered Rexahn Pharmaceuticals Inc. recorded
a trading volume of 111,993 shares. The stock ended the session 1.69% lower at $2.32. The Company's
shares have surged 63.50% on an YTD basis. The stock is trading 16.89% below its 200-day moving average. Moreover, shares of
Rexahn Pharma, which discovers, develops, and commercializes treatments for cancer, have a Relative Strength Index (RSI) of
27.88.
On July 10 th, 2017, Rexahn Pharma announced that the US Patent and Trademark Office
has issued a Notice of Allowance for US Patent Application No. 15/178,390, "Fluorocyclopentenylcytosine Methods of Use". The
patent application covers indications, dosage regimens, and pharmacokinetic profile for RX-3117. The patent is expected to
be issued within a few months from the notice of allowance, and is expected to provide protection to 2036. The free research
report on RNN is available at: http://dailystocktracker.com/registration/?symbol=RNN
Protalix BioTherapeutics
Karmiel, Israel-based Protalix BioTherapeutics Inc.'s stock closed the day 1.26% lower at
$0.79 with a total trading volume of 231,701 shares. The Company's shares have advanced 77.53%
since the start of this year. The stock is trading 3.88% above its 200-day moving average. Additionally, shares of Protalix
BioTherapeutics, which focuses on the development and commercialization of recombinant therapeutic proteins based on its
proprietary ProCellEx protein expression system in Israel and internationally, have an RSI of
46.79. The complimentary report on PLX can be downloaded at: http://dailystocktracker.com/registration/?symbol=PLX
Navidea Biopharma
Shares in Dublin, Ohio headquartered Navidea Biopharmaceuticals Inc recorded a trading volume
of 161,898 shares. The stock ended yesterday's trading session 1.47% lower at $0.48. The Company's
shares have advanced 1.50% in the previous three months. The stock is trading below its 50-day moving average by 3.68%.
Furthermore, shares of Navidea Biopharma, which focuses on the development and commercialization of precision immunodiagnostic
agents and immunotherapeutics, have an RSI of 43.50.
On June 20 th, 2017, Navidea Biopharma announced that it has entered into an
exclusive license and distribution agreement with Sayre Therapeutics for the development and commercialization of Tc 99m
tilmanocept in India. Under the terms of the agreement, the former received an upfront payment,
and is eligible to receive upcoming milestone payments and double-digit royalties associated with the sale of Tc 99m tilmanocept.
Visit us today and download our complete research report on NAVB for free at: http://dailystocktracker.com/registration/?symbol=NAVB
Biostage
Holliston, Massachusetts headquartered Biostage Inc.'s stock finished Tuesday's session 0.93%
lower at $0.53. A total volume of 1.68 million shares was traded, which was above their three
months average volume of 741,520 shares. The Company's shares have surged 64.50% in the last one month and 78.96% over the
previous three months. The stock is trading above its 50-day moving average by 54.35%. Additionally, shares of Biostage, which
engages in developing bioengineered organ implants based on its Cellframe technology, have an RSI of 70.37.
On July 10 th, 2017, Biostage announced that the NASDAQ Hearings Panel (the "Panel")
has granted the Company's request for continued listing on NASDAQ. The continued listing is subject to a number of conditions,
with the Panel's decision ultimately requiring that the Company evidence full compliance with all requirements for continued
listing on The NASDAQ Capital Market, including the $1.00 bid price and $2.5 million stockholders' equity
requirements, by no later than November 13th, 2017. Get free access to your technical report on BSTG at: http://dailystocktracker.com/registration/?symbol=BSTG
--
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent
departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES :
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a
third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on
analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"),
provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary,
based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a
reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the
information herein. The Reviewer has only independently reviewed the information provided by the Author according to the
procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party
research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside
of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document.
Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing
of the information, or (2) warrant any results from use of the information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities
mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers
in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you ' re a company we are covering and wish to no longer feature on our coverage list contact us via email
and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA